Detroit-based Barbara Ann Karmanos Cancer Institute has become the first independent cancer center in the U.S. to provide a one-time gene therapy for the treatment of hemophilia B in adults.
The first patient received the therapy — called Hemgenix — Oct. 28, according to a March 23 news release from the cancer institute.
The standard treatment for hemophilia B requires routine infusions of factor IX replacement therapy to help reduce bleeding risk. After gene therapy, patients need infusions only when undergoing a medical procedure or experiencing physical trauma.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
